Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

status epilepticus

What is Status Epilepticus?

Status epilepticus (SE) is an extremely serious and often fatal medical emergency. It may be defined as a continuous seizure which lasts for 30 minutes or more, or as 2 or more seizure episodes without the patient recovering full consciousness in between any 2 episodes.   It is thought to be due to the lack of efficacy of GABA-ergic activity which is typically responsible for terminating abnormal electrical activity in the brain. Once SE is in progress, it should be treated by benzodiazepines, with fosphenytoin being added if required. If the patient does not respond, but has persistent seizures, a second-line drug is administered, such as a barbiturate, Propofol, sodium valproate, levetiracetam or topiramate, according to the situation and the facilities available. The patient must a...

Status Epilepticus Risk Factors and Complications

Status epilepticus (SE) is a condition in which seizure activity in the brain persists for prolonged periods of time. It is associated with significant mortality of 15-22% in adults and has a high complication rate. The potential complications are multi-organ in range and may occur at any stage of SE. The early detection and treatment of complications is a crucial step in ensuring the best prognosis for SE. Risk Factors Epidemiological studies and case series have led to the following conclusions: Generalized CSE accounts for almost three of every four cases of SE. The incidence in the US is about 41 or more per 100 000 population The recurrence rate is about 13% Infants below the age of one year and the elderly who are above 60 years are at highest risk of SE. 40% occur below the age of 2...

What is Status Epilepticus?

Status epilepticus (SE) is an extremely serious and often fatal medical emergency. It may be defined as a continuous seizure which lasts for 30 minutes or more, or as 2 or more seizure episodes without the patient recovering full consciousness in between any 2 episodes.   It is thought to be due to the lack of efficacy of GABA-ergic activity which is typically responsible for terminating abnormal electrical activity in the brain. Once SE is in progress, it should be treated by benzodiazepines, with fosphenytoin being added if required. If the patient does not respond, but has persistent seizures, a second-line drug is administered, such as a barbiturate, Propofol, sodium valproate, levetiracetam or topiramate, according to the situation and the facilities available. The patient must a...

Population-Based Study Helps Predict Outcomes in Status Epilepticus

Convulsive status epilepticus (CSE) in children without prior neurologic abnormalities is not associated with long-term cognitive or other neurologic deficits, according to a large new population-based study published online December 5, 2017 in The Lancet Child and Adolescent Health.   Previous smaller, hospital-based studies had reached similar conclusions, but independent experts told Neurology Today that the size, duration, and structure of this study, which included participants in the north London convulsive status epilepticus surveillance study cohort, allows clinicians to offer stronger reassurance to parents of children with CSE, defined as continuous or rapid sequential seizure activity for 30 minutes or more.   “This reinforces some of what we already knew, but fo...

Status Epilepticus Redefined.

Status Epilepticus is a prolonged seizure that can have dire consequences for the individual who is suffering it. There has been some confusion as to what timeframe or length of seizure is considered an SE event. Emergency Treatment has traditionally been started at about 5 minutes of seizure duration and SE declared at about 30 minutes. “The problem has been that you had these two definitions floating around,” that included 5 minutes or 30 minutes, depending on whether you were talking about when to treat or consequences, said study author Shlomo Shinnar, MD, PhD, professor, neurology, pediatrics and epidemiology and population health, and director, Comprehensive Epilepsy Management Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.

Sage’s Drug For Rare Epilepsy Shows Promise in Small Study

Sage Therapeutics isn’t the company its founders originally intended. Third Rock Ventures started Sage in 2011 to develop drugs for big neurological disorders such as schizophrenia and traumatic brain injury. Along the way, however, the Cambridge, MA-based company decided to focus on rare neurological disorders that could be moved quickly through the clinic. That switch is proving prescient so far: Sage got the full top-line data from its first clinical trial today, and the results are promising. Sage (NASDAQ: SAGE) reports that SAGE-547, its lead drug, met all primary and secondary goals in a small, 12-patient clinical trial for super-refractory status epilepticus (SRSE), a rare, life-threatening form of epilepsy characterized by continuous or repeating seizures. Patients with the conditi...

STATUS EPILEPTICUS – Some Children ‘Have Long-term Damage’

A new study has found that a subgroup of children who suffer from convulsive status epilepticus – an epileptic seizure that lasts 30 minutes or longer, or clusters of prolonged seizures – may experience long-term brain damage years after. This is according to research presented at the American Epilepsy Society’s 67th Annual Meeting. The researchers, led by Suresh Pujar of the Institute of Child Health at Imperial College London in the UK, say it has long been believed that the most common form of childhood convulsive status epilepticus (CSE) – called prolonged febrile (fever-induced) seizures (PFS) – is a cause of mesial temporal sclerosis (MTS). MTS is defined as a scarring of the hippocampus in the brain and loss of neurons. But the investigators note that i...

PRESS RELEASE: First Study of Diazepam Nasal Spray in People with Epilepsy Shows Feasibility of Dosing During Seizure

ARDSLEY, N.Y.–(BUSINESS WIRE)–June 26, 2013– Study presented at the 30(th) International Epilepsy Congress also showed pharmacokinetic and safety profile consistent with previous studies in healthy volunteers Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced results of the first clinical study to assess pharmacokinetics, safety and tolerability of Diazepam Nasal Spray in people with epilepsy. Study findings were presented on June 25 at the biennial International Congress of the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE), being held in Montreal, Canada. Diazepam Nasal Spray is being developed for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures. “The stu...

Study examines developmental delays in children within six weeks of CSE

Researchers from the UK determined that developmental delays are present in children within six weeks following convulsive status epilepticus (CSE)-a seizure lasting longer than thirty minutes. The study appearing today in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE), suggests that neurodevelopmental impairments continue to be present one year after CSE.

Lost Password

Register